Supplements promise a lot, and those marketed as appetite suppressants promise more than most: eat less, want less, lose weight without the daily struggle. The natural supplement aisle is crowded with claims like these. The uncomfortable truth is that very few of them have ever been tested in a way that would satisfy a scientist, a physician, or a careful buyer.
Calocurb® is built to be the exception. Its effect is not argued with marketing language; it is measured in randomized, double-blind, placebo-controlled human trials, the same standard used to test pharmaceutical drugs. The most recent of these, Calocurb's fourth clinical trial (C4), followed 150 adults for 24 weeks and tracked what actually changes in the body: body weight, fat mass, visceral fat, and muscle.
This article walks through that evidence. It covers how the C4 study was designed, who it studied, what it found, and what those findings mean for anyone weighing a natural appetite suppressant against the alternatives.
6.5×
Greater fat loss vs. placebo in Calocurb's 24-week clinical trial
9.5×
Greater body weight loss vs. placebo over 24 weeks
5.3%
Muscle-adjusted weight loss — fat lost, lean mass preserved
Do natural appetite suppressants actually work?
The honest answer is that most don't. The majority of natural appetite suppressants have not shown consistent weight loss effects in controlled human trials that have been published in peer-reviewed journals, and the category is full of confident claims that rest on thin or nonexistent evidence. This isn't an argument against supplements. It is simply the current state of the field, and knowing it is the first step to evaluating any product fairly.
Two broad categories frame the landscape: prescription medications, which are rigorously tested but come with cost, access, and side-effect trade-offs, and natural or over-the-counter options, where the evidence ranges from decent to none at all. It is worth understanding how prescription and natural appetite suppressants differ before looking at any single product.
Prescription options
Appetite is not a matter of willpower alone. It is regulated by hormones such as ghrelin, which signals hunger, and leptin, which signals fullness, alongside insulin and cortisol. Other hormones also contribute to feeling full, including glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK), and peptide tyrosine tyrosine (PYY). Neurotransmitters like serotonin and dopamine shape reward and satiety, and signals travel constantly between the gut and the brain along the gut-brain axis. The hypothalamus acts as the brain's control center, integrating all of it. This is why hormone activity matters so much, and it is exactly where Amarasate acts.
Several FDA-approved medications work on these systems. GLP-1 receptor mimics such as semaglutide (Wegovy®/Ozempic®) and liraglutide (Saxenda®) slow gastric emptying and signal fullness. The dual GLP-1/GIP receptor activator tirzepatide (Zepbound®/Mounjaro®) includes a mimic of GIP (glucose-dependent Insulinotropic polypeptide), another gut hormone that acts centrally in the brain to reduce food intake and also promotes healthy fat storage. Orlistat blocks fat absorption, while stimulant-based options such as naltrexone-bupropion (Contrave®) and phentermine-topiramate (Qsymia®) act on the central nervous system through neurotransmitters. These can produce meaningful weight loss, but they carry real trade-offs: side effects, ongoing cost, prescription barriers, and, notably, a share of the weight lost is lean muscle rather than fat.
Natural and OTC options
Natural options fall into a few groups. Fiber-based ingredients such as glucomannan and psyllium can offer some satiety support, with modest evidence. Stimulant-based options such as caffeine and green tea extract show limited and inconsistent results. Ingredients marketed as hormone-influencing generally have little rigorous human trial data behind them.
It is worth being plain: most over-the-counter supplements are unregulated and untested, and "natural" does not automatically mean safe or effective. That is a statement of fact, not a criticism. There is, however, one exception worth examining, and it helps to see how it compares with berberine and Akkermansia. One natural supplement has completed four peer-reviewed human clinical trials, including a 24-week study measuring fat loss and body composition. That is the subject of the rest of this article.
What is Amarasate and how does it work?
Amarasate is a patented extract derived from New Zealand bitter hop flowers, (Humulus lupulus L.). It is 100% plant-based, contains no stimulants, and requires no prescription. It is delivered in a delayed-release capsule designed to activate in the small intestine, where the hormone response is strongest, and it begins working within about an hour of taking it.
The three-hormone mechanism
Amarasate works by activating bitter taste receptors, known as TAS2Rs, that line the gut. In Calocurb's human trials, this activation triggered the release of three hormones that regulate appetite:
- GLP-1 signals fullness to the brain and slows gastric emptying, which supports weight loss.
- CCK slows stomach emptying, , enhances leptin secretion, and aids in fat digestion..
- PYY reduces hunger signals and increases fullness in the brain, and has been linked to pathways involved in muscle maintenance and recovery.
These responses are not theoretical. In a study that directly measured the blood levels of these and other hormones, Amarasate raised GLP-1, CCK, and PYY well above their normal levels (by 640%, 600%, and 170%, respectively), and reduced energy intake at the following meals by 18%.1 In 24-hour fasting studies, the extract produced meaningful reductions in hunger (by 20% in men and 30% in women)s and cravings (by 40% in women).23 It's encouraging that the fat-loss and body-composition results in the 24-week C4 trial are consistent with this same three-hormone response seen in the first 3 short-term studies.
How this differs from pharmaceutical GLP-1s
Pharmaceutical GLP-1 receptor activators (so-called "agonists") like semaglutide (Wegovy/Ozempic) deliver a synthetic hormone analog or mimic that replaces or overrides the body's own signaling, while tirzepatide (Zepbound/Mounjaro) is dual agonist of both GLP-1 and GIP receptors. Amarasate works further upstream. Instead of supplying a hormone mimic, it prompts the release of the body's own GLP-1, CCK, and PYY through the gut's bitter taste receptor pathway. The result is endogenous hormone activation rather than pharmaceutical substitution: no needle, no prescription, and no synthetic compound. For a fuller picture, see natural and injectable approaches to GLP-1.
(You may be wondering why this bitter taste receptor pathway exists. Many poisonous substances are very bitter, so it's a protective mechanism to prevent ongoing intake of something that may be harmful.)
See the full science behind Amarasate on Calocurb's science page.
The clinical evidence behind Amarasate: four human trials
The C4 results don't stand alone. They are the culmination of a $30M research program spanning more than 15 years and built on three earlier trials that established how Amarasate works across different people and conditions. You can review the full clinical evidence on the science page.
Studies 1 through 3 proved the mechanism: that Amarasate reliably triggers satiety hormones and reduces hunger and food intake. Study 4, the C4 trial, answered the question that matters most for anyone considering it: Does that hormonal activity actually translate into fat loss?
| Study | Published | What it measured | Key finding |
|---|---|---|---|
| Study 1* | Am J Clin Nutr, 2022 | Satiety hormones and energy intake (men) | Increase in GLP-1 6.4x, CCK 6.0x, PYY 1.7x above baseline; 18% reduction in energy intake.4 |
| Study 2 | Nutrients, 2019 | Hunger during a 24-hour fast (men) | 20reduction in hunger vs. placebo.5 |
| Study 3 | Obesity Pillars, 2024 | Cravings and hunger (women, fasting) | 40% reduction in cravings, 30% reduction in hunger, 14% decrease in energy intake (at least 4 hours after last dose of Amarasate).6 |
| Study 4 (C4) | Obesity Pillars, 2026 | Body weight, fat mass, visceral fat, muscle mass | See the section below.7 |
*Note that C1 was published after C2, but occurred prior to it, proving that Amarasate significantly increased hormone levels and justifying ongoing research.
Calocurb's 4th clinical trial
Study design
Conducted in 2025, the C4 trial used the gold-standard design: randomized, double-blind, and placebo-controlled, the same methodology required of pharmaceutical drug trials. It enrolled 150 overweight and obese adults, all with a BMI of 25 kg/m² to 35 kg/m² and aged 18 to 45, and ran for 24 weeks in a parallel design. Of the 150 who started, 128 completed the trial, split between the treatment and placebo groups. Participants took a 500 mg daily dose of Amarasate as two 125 capsules an hour before their two main meals; this dose was, titrated up gradually over the first three weeks. two. The study was submitted for publication in the peer-reviewed journal Obesity Pillars in 2026.
Two design choices strengthen the result. First, the randomized, double-blind, placebo-controlled structure eliminates bias, isolates the treatment effect, and produces replicable data. Second, participants were given only minimal lifestyle dietary and exercise advice through monthly group seminars. That was deliberate: it isolated Calocurb's effect and mimicked real-world conditions, where most people are not following a strict program of lifestyle training.
What the study measured and what it found
The results are best read directly, then explained.
| Outcome measure | Calocurb | Placebo |
|---|---|---|
| Body weight change | -8.4 lb / -3.8 kg (-4.3%) | -0.9 lb / -0.4 kg (-0.5%) |
| Fat mass change | -9.9 lb / -4.5 kg | -1.5 lb / -0.7 kg |
| Visceral fat area | -5.0 in² / -32.5 cm² | -1.4 in² / -9.1 cm² |
| Muscle mass change | +2.0 lb / +0.9 kg | +0.4 lb / +0.2 kg |
| Muscle mass-adjusted weight loss | -5.3% | -0.7% |
Over 24 weeks, participants taking Calocurb lost 8.4 lb (3.8 kg), a 4.3% reduction in body weight, compared with almost no change in the placebo group — a 9.5 times greater loss.8 Fat mass fell by (9.9 lb) 4.5 kg versus 1.5 lb (0.7 kg) on placebo, over 6.5 times greater, and visceral fat, the metabolically active dangerous fat around the organs, dropped by over 5 in² (32.5 cm²) compared with 1.4 in² (9.1 cm²), roughly 3.5 times greater.9 All these differences were statistically significant when comparing the starting and end measurements in the Calocurb group or the comparing the results between the Calocurb group and the placebo group.10 In contrast, the people receiving placebo had no statistically significant change from their initial to ending measurements.11
Just as important, muscle mass was not lost. Participants on Calocurb actually gained a small amount of lean mass rather than shedding it, which is why the muscle-adjusted weight loss reached 5.3% when the gain in muscle mass is taken into account (the "muscle mass-adjusted weight" shown in the table). While this didn't reach statistical significance, the preservation of muscle mass with Calocurb is in stark contrast to what typically occurs with either standard dieting or medication/surgery assisted weight loss. You can read more about muscle loss here.
Body weight change adjusted for gain in muscle (%) over 24 weeks: 53% loss for Calocurb vs. 0.7% for placebo at 24 weeks.12
The trend line tells its own story: steady, sustained weight loss across the full 24 weeks for the Calocurb group, while placebo participants saw modest early losses that plateaued and mostly reversed. Because the study used minimal lifestyle interventions, the sustained separation is particularly notable. It also matters that the loss was concentrated in fat, especially visceral fat. For anyone concerned about tolerability, it is worth reading whether Calocurb is safe.
How does this compare to pharmaceutical options?
For orientation, it helps to place these numbers next to pharmaceutical benchmarks, with one important caveat. Reported average weight losses in real-world use include:
- Orlistat: more modest losses, as it works by blocking fat absorption rather than acting on appetite.
- Liraglutide (Saxenda): around 5%.13
- Semaglutide (Wegovy): around 11% in "real world" use.14
- Tirzepatide (Zepbound): 13% in "real world use".15
There is a crucial difference in what these figures represent. The pharmaceutical percentages include lean muscle lost alongside fat. Calocurb's muscle-adjusted result of 5.3% reflects fat loss with muscle preserved, so the two should not be read as a head-to-head comparison. What the C4 data shows is a clinically meaningful result for a natural supplement: no prescription, no injection, and none of the pharmaceutical side-effect profile. This also matters for anyone thinking about what happens when you stop taking an injectable.
Change (Δ) in muscle mass (kg) over 24 weeks: +0.9 kg for Calocurb vs. +0.2 kg for placebo at 24 weeks.16
Note: neither the between-group nor baseline-endpoint differences in muscle mass were statistically significant.
You've now seen the full picture: fat loss, less visceral fat, and muscle preserved, all measured over 24 weeks. Calocurb starts working within an hour of your first dose. Try Calocurb.
Four clinical trials. No prescription.
The only natural supplement with 24-week fat loss data
Calocurb activates your body's own GLP-1, CCK, and PYY through bitter taste receptors in the gut. No needle, no synthetic hormone, no prescription required.
